Dahlia Biosciences
RNA analysis tools for research and diagnostic applications
* Data source: Crunchbase
- Founded
- 2017
- Employees*
- 1-10
- Funding to Date*
- undisclosed
- Website
- dahliabio.com
"Flow cytometry is a powerful technology to study complex cell populations, and is ubiquitous in the development of immuno-oncology and cell based therapies. We see a significant opportunity to scale single-cell RNA analysis to millions of cells by combining the throughput of flow cytometry with our CRISPR-based RNA detection reagents."
The flow cytometry research market is estimated to be >$1.9 billion in 2020 growing 7%, of which approximately $1.3B is driven by annual reagents expenditures.
Dahlia Biosciences is providing the next generation of multiplexed in situ single-cell RNA analysis tools for research and diagnostic applications. Our vision is to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells.
More Companies
